CJC-1295 w/o DAC +IPA (Ipamorelin)

Description

CJC-1295 (w/o DAC) + IPA (Ipamorelin) | 10mg | Growth Hormone Secretagogue Research Blend

Description

The CJC-1295 (w/o DAC) + Ipamorelin blend combines two peptides commonly used in laboratory research to investigate growth hormone secretagogue pathways. Each vial contains a total of 10mg of lyophilized peptide composed of 5mg CJC-1295 (without DAC) and 5mg Ipamorelin, providing a complementary model system for studying endocrine signaling dynamics.

CJC-1295 (without DAC) is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH) designed to stimulate growth hormone signaling through receptor activation in pituitary somatotroph cells. Unlike the DAC-modified version, the non-DAC configuration provides a shorter functional duration in experimental systems, allowing researchers to model pulsatile growth hormone release patterns.

Ipamorelin is a selective agonist of the ghrelin receptor (GHS-R1a) and is frequently studied for its ability to stimulate growth hormone release through a pathway distinct from GHRH receptor signaling. When combined with CJC-1295, the two peptides provide a dual-pathway model for examining growth hormone axis regulation, receptor selectivity, and peptide synergy in controlled laboratory environments.

This vial contains 10mg of lyophilized peptide blend (5mg CJC-1295 w/o DAC + 5mg Ipamorelin) intended strictly for controlled in vitro laboratory research applications.

Specifications

• Product Name: CJC-1295 (w/o DAC) + Ipamorelin Research Blend
• Blend Composition: 5mg CJC-1295 (w/o DAC) + 5mg Ipamorelin
• Unit Size: 10mg total peptide per vial
• Form: Lyophilized peptide powder
• Solubility: Soluble in sterile water or compatible aqueous buffers according to laboratory protocols
• Storage: Store lyophilized material at −20 °C in a sealed container protected from light and moisture; refrigerate reconstituted solutions at 2–8 °C according to laboratory protocol

Research Applications

Growth Hormone Secretagogue Pathway Research

This peptide blend is widely used in laboratory studies examining growth hormone secretagogue signaling pathways. Researchers analyze how multiple receptor systems interact to regulate endocrine signaling within pituitary cell models.

Pulsatile Growth Hormone Release Modeling

The non-DAC configuration of CJC-1295 allows researchers to investigate pulsatile growth hormone secretion patterns. These models are useful for studying physiological hormone release dynamics and endocrine feedback mechanisms.

Ghrelin Receptor Activation Research

Ipamorelin is frequently used in experimental systems to examine ghrelin receptor (GHS-R1a) activation and downstream signaling pathways. These studies help characterize receptor specificity and hormone secretion mechanisms.

Synergistic Peptide Interaction Research

By combining a GHRH analog with a ghrelin receptor agonist, this blend allows researchers to study synergistic interactions between distinct growth hormone secretagogue pathways within controlled experimental conditions.

Pituitary Cell Signaling Research

The blend is also utilized in pituitary cell assays investigating receptor-mediated signaling, intracellular response pathways, and hormone secretion dynamics associated with growth hormone regulatory systems.

Comparative Peptide Pharmacology Research

Researchers frequently use this combination to compare signaling characteristics between short-acting releasing hormone analogs and ghrelin receptor agonists, helping to characterize peptide pharmacology and receptor pathway behavior.

Intended Use

Intended strictly for in vitro laboratory research use.

Legal Disclaimer

This product has not been evaluated by the U.S. Food and Drug Administration. No claims are made regarding the treatment, diagnosis, cure, or prevention of any disease. All information provided is intended strictly for scientific and educational purposes only.

Terms of Sale

All sales are final